Search Results
Search for other papers by Can Liu in
Google Scholar
PubMed
Search for other papers by Mian Zhang in
Google Scholar
PubMed
Search for other papers by Meng-yue Hu in
Google Scholar
PubMed
Search for other papers by Hai-fang Guo in
Google Scholar
PubMed
Search for other papers by Jia Li in
Google Scholar
PubMed
Search for other papers by Yun-li Yu in
Google Scholar
PubMed
Search for other papers by Shi Jin in
Google Scholar
PubMed
Search for other papers by Xin-ting Wang in
Google Scholar
PubMed
Search for other papers by Li Liu in
Google Scholar
PubMed
Search for other papers by Xiao-dong Liu in
Google Scholar
PubMed
, it is noteworthy that local high concentration of ginsenosides in intestine may interact with intestinal epithelium, where numerous endocrine cells are located. Glucagon-like peptide-1 (GLP1), secreted by enteroendocrine L-cells, is one of the most
Eastern Clinical Research Unit, Department of Diabetes and Endocrinology, Biotechnology Division, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia
Search for other papers by Hongbin Liu in
Google Scholar
PubMed
Eastern Clinical Research Unit, Department of Diabetes and Endocrinology, Biotechnology Division, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia
Search for other papers by Yunshan Hu in
Google Scholar
PubMed
Eastern Clinical Research Unit, Department of Diabetes and Endocrinology, Biotechnology Division, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia
Search for other papers by Richard W Simpson in
Google Scholar
PubMed
Eastern Clinical Research Unit, Department of Diabetes and Endocrinology, Biotechnology Division, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia
Search for other papers by Anthony E Dear in
Google Scholar
PubMed
Introduction Glucagon-like peptide-1 (GLP-1), an incretin first identified in 1984, has been proposed as a potential candidate target for therapy in the treatment of type 2 diabetes ( Nauck et al . 1993 , Edwards 2005 ). GLP-1, the product of the
Unit of Animal Biology, Université catholique de Louvain, Brussels, Belgium
Search for other papers by Patrice D Cani in
Google Scholar
PubMed
Unit of Animal Biology, Université catholique de Louvain, Brussels, Belgium
Search for other papers by Catherine A Daubioul in
Google Scholar
PubMed
Unit of Animal Biology, Université catholique de Louvain, Brussels, Belgium
Search for other papers by Brigitte Reusens in
Google Scholar
PubMed
Unit of Animal Biology, Université catholique de Louvain, Brussels, Belgium
Search for other papers by Claude Remacle in
Google Scholar
PubMed
Unit of Animal Biology, Université catholique de Louvain, Brussels, Belgium
Search for other papers by Grégory Catillon in
Google Scholar
PubMed
Unit of Animal Biology, Université catholique de Louvain, Brussels, Belgium
Search for other papers by Nathalie M Delzenne in
Google Scholar
PubMed
( Reimer & McBurney 1996 , Cani et al. 2004 ). In the intestine, the post-translational modification of the proglucagon gene by prohormone convertase 1 (PC1) leads to the production of glucagon-like peptide-1(7–36) amide (GLP-1(7–36) amide) which, among
Australian Centre for Blood Diseases, Eastern Clinical Research Unit, Novo Nordisk A/S, Department of Diabetes and Endocrinology, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia
Search for other papers by Hongbin Liu in
Google Scholar
PubMed
Australian Centre for Blood Diseases, Eastern Clinical Research Unit, Novo Nordisk A/S, Department of Diabetes and Endocrinology, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia
Search for other papers by Anthony E Dear in
Google Scholar
PubMed
Search for other papers by Lotte B Knudsen in
Google Scholar
PubMed
Australian Centre for Blood Diseases, Eastern Clinical Research Unit, Novo Nordisk A/S, Department of Diabetes and Endocrinology, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia
Australian Centre for Blood Diseases, Eastern Clinical Research Unit, Novo Nordisk A/S, Department of Diabetes and Endocrinology, Monash University, 6th Floor Burnett Tower, 89 Commercial Road, Prahran 3181, Melbourne, Victoria, Australia
Search for other papers by Richard W Simpson in
Google Scholar
PubMed
protected from the development of biochemical abnormalities associated with endothelial cell dysfunction and development of atherosclerosis ( Eitzman et al . 2000 , Mao et al . 2004 ). Liraglutide, an acylated glucagon-like peptide-1 (GLP-1) analogue, has
Chemicon International Inc., 28820 Single Oak Drive, Temecula, California 92590, USA
Search for other papers by Neville H McClenaghan in
Google Scholar
PubMed
Chemicon International Inc., 28820 Single Oak Drive, Temecula, California 92590, USA
Search for other papers by Peter R Flatt in
Google Scholar
PubMed
Chemicon International Inc., 28820 Single Oak Drive, Temecula, California 92590, USA
Search for other papers by Andrew J Ball in
Google Scholar
PubMed
-cell desensitisation compared with sulphonylureas may occur following prolonged exposure to nateglinide ( Ball et al. 2004 b ). In vivo , insulin secretion can be stimulated by glucagon-like peptide-1 (GLP-1), a hormone of the enteroinsular axis, released
Search for other papers by L Bai in
Google Scholar
PubMed
Search for other papers by G Meredith in
Google Scholar
PubMed
Search for other papers by B E Tuch in
Google Scholar
PubMed
Introduction Glucagon-like peptide-1 (GLP-1) is a peptide secreted from the gut in response to food. It acts directly on β cells, enhancing the effect of glucose in stimulating insulin secretion from these cells. When administered to
Search for other papers by Hong Lan in
Google Scholar
PubMed
Search for other papers by Galya Vassileva in
Google Scholar
PubMed
Search for other papers by Aaron Corona in
Google Scholar
PubMed
Search for other papers by Li Liu in
Google Scholar
PubMed
Search for other papers by Hana Baker in
Google Scholar
PubMed
Search for other papers by Andrei Golovko in
Google Scholar
PubMed
Search for other papers by Susan J Abbondanzo in
Google Scholar
PubMed
Search for other papers by Weiwen Hu in
Google Scholar
PubMed
Search for other papers by Shijun Yang in
Google Scholar
PubMed
Search for other papers by Yun Ning in
Google Scholar
PubMed
Search for other papers by Robert A Del Vecchio in
Google Scholar
PubMed
Search for other papers by Frederique Poulet in
Google Scholar
PubMed
Search for other papers by Maureen Laverty in
Google Scholar
PubMed
Search for other papers by Eric L Gustafson in
Google Scholar
PubMed
Search for other papers by Joseph A Hedrick in
Google Scholar
PubMed
Search for other papers by Timothy J Kowalski in
Google Scholar
PubMed
fall into two major categories: drugs that improve insulin sensitivity, and those that increase insulin secretion from β-cells. Agents that enhance insulin secretion in a glucose-dependent manner, such as glucagon-like peptide-1 (GLP-1) mimetics (e
School of Pharmaceutical and Biological Sciences, Aston University, Birmingham, UK
Search for other papers by B D Green in
Google Scholar
PubMed
School of Pharmaceutical and Biological Sciences, Aston University, Birmingham, UK
Search for other papers by N Irwin in
Google Scholar
PubMed
School of Pharmaceutical and Biological Sciences, Aston University, Birmingham, UK
Search for other papers by V A Gault in
Google Scholar
PubMed
School of Pharmaceutical and Biological Sciences, Aston University, Birmingham, UK
Search for other papers by C J Bailey in
Google Scholar
PubMed
School of Pharmaceutical and Biological Sciences, Aston University, Birmingham, UK
Search for other papers by F P M O’Harte in
Google Scholar
PubMed
School of Pharmaceutical and Biological Sciences, Aston University, Birmingham, UK
Search for other papers by P R Flatt in
Google Scholar
PubMed
Introduction The incretin hormone glucagon-like peptide-1 (GLP-1) has potent insulinotropic effects on pancreatic β-cells, and further promotes glucose lowering by enhancing glucose uptake and glyconeogenesis in peripheral tissues
Search for other papers by Patricia Vázquez in
Google Scholar
PubMed
Search for other papers by Isabel Roncero in
Google Scholar
PubMed
Search for other papers by Enrique Blázquez in
Google Scholar
PubMed
Search for other papers by Elvira Alvarez in
Google Scholar
PubMed
Introduction Glucagon-like peptide-1(7–36)amide (GLP-1) is an intestinal peptide synthesised in L-cells. It is also produced in the brain ( Jin et al. 1988 , Kreymann et al. 1989 ), where it exerts some effects on
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Thomas H Claus in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Clark Q Pan in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Joanne M Buxton in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Ling Yang in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Jennifer C Reynolds in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Nicole Barucci in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Michael Burns in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Astrid A Ortiz in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Steve Roczniak in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by James N Livingston in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Kevin B Clairmont in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by James P Whelan in
Google Scholar
PubMed
Introduction Glucagon-like peptide-1 (GLP-1) is a potent endogenous modulator of insulin secretion that is released by the L-cells in the crypts of the jejunum and ileum in response to a meal ( Kieffer & Habener 1999 ). Its function